Background: Klebsiella pneumoniae is an opportunistic pathogen and many strains are multidrug resistant. KPC is one of the most problematic resistance mechanisms, as it confers resistance to most b-lactams, including carbapenems. A promising platform technology for treating infections caused by MDR pathogens is the nucleic acid-like synthetic oligomers that silence bacterial gene expression by an antisense mechanism.
Introduction
Antibiotic resistance is a global threat. 1 The percentage of isolates with MDR is increasing for many bacterial pathogens. 2, 3 In the USA, 2 million persons annually become severely infected with antibiotic-resistant bacteria and 23 000 of them die. In Europe, antibiotic-resistant bacteria kill at least 25 000 annually.
The main strategies for keeping ahead in the race against resistance have been to discover new antibiotics, chemically modify old ones so that they are not recognized as substrates for resistance mechanisms, or combine antibiotics with inhibitors of resistance. [4] [5] [6] [7] However, these strategies have not kept pace with the spread of resistance. Discovery of novel antibiotics has waned, effective modifications have become less frequent, inhibitors of resistance are limited to a few b-lactamases, and economic factors in the pharmaceutical industry dried up the developmental pipeline. As a result, a novel antibiotic scaffold effective against Gram-negative pathogens has not been approved in over 30 years. 4, 8 Some of the most problematic pathogens are a group of Gram-negative bacteria that includes Klebsiella pneumoniae.
9,10
K. pneumoniae is carried asymptomatically in the intestines and nasopharynx by a highly variable percentage of the population. 11 It is an opportunistic pathogen that can infect many tissues, but is mostly associated with urinary tract infections, pneumonia, sepsis, skin infections and meningitis. Like other organisms in this group, K. pneumoniae has acquired an impressive array of antibiotic resistance mechanisms against all classes of antibiotics and the frequency of MDR isolates is growing. 2, 10 An alternative strategy for discovering and developing new antimicrobials is to synthesize nucleic acid mimetics that bind to specific bacterial RNA and inhibit growth. Phosphorodiamidate morpholino oligomers (PPMOs) are synthetic nucleotide analogues that prevent translation of a specific gene by selectively binding mRNA in an antisense manner.
12, 13 The structure differs from DNA by a morpholino ring that replaces the deoxyribose ring, and a charge-neutral phosphorodiamidate linker instead of the phosphodiester linker.
14 An arginine-rich peptide is conjugated to one or the other end of the PPMO to enable penetration through the Gram-negative outer membrane. 15, 16 Currently, we have designed, synthesized and tested PPMOs targeted to a variety of essential genes in K. pneumoniae. We show here a proof-of-concept that a PPMO targeted to acpP (encoding an acyl carrier protein that is essential for lipid biosynthesis) protected mice in a lethal model of pneumonia. To our knowledge, this is the first time a gene-specific therapeutic agent has been shown to be effective against K. pneumoniae in vivo.
Materials and methods

Reagents
All PPMOs were synthesized and purified at Sarepta Therapeutics (Corvallis, Oregon, USA) as described previously. 17 The PPMO nucleobase and amino acid sequences are shown in Table S1 (available as Supplementary data at JAC Online). Crystal violet was from Acros Chemical Co. (Geel, Belgium).
Bacterial strains, culture cells and growth conditions
K. pneumoniae OR1-OR20 are clinical isolates that were provided by Karim E. Morey (Oregon Public Health Laboratory, Portland, OR, USA). K. pneumoniae BAA-2146 and human A549 lung epithelial cells were obtained from ATCC (Manassas, VA, USA). K. pneumoniae NDM1-A, -B, -C and -D were provided by Susan M. Poutanen (Mount Sinai Hospital, Toronto, ON, Canada). K. pneumoniae 3190, 3290, 3426 and 3427 were provided by Carl Urban (New York Queens Hospital, NY, USA). K. pneumoniae NIH-1 and NIH-2 were provided by Karen Frank (NIH, Bethesda, MD, USA). All other strains were provided by BEI Resources (Manassas, VA, USA). Liquid cultures were grown in Mueller-Hinton II (MHII) (cation adjusted) broth. LB agar was used for growth on solid medium. Bacteria for in vivo studies were prepared from a log-phase culture. The culture was cooled on ice and the cells washed twice with icecold PBS by centrifugation (3%10 3 g). The washed cells were resuspended in PBS/10% glycerol to about 1%10 11 cfu/mL and stored frozen at #75 C.
MIC and MBC
MICs were measured by the CLSI microdilution method. 18 MBCs were measured by diluting and plating on LB agar samples from wells without visible growth after 20 h. The Petri dishes were incubated overnight at 37 C and the colonies were counted.
Cytotoxicity
Human lung epithelial cells (A549) were cultured with or without 10 lM PPMO as described in Figure S1 . After 48 h, viable cells were measured by trypan blue exclusion. 19 
Biofilm
Biofilms were grown for 24 h and measured as described previously, 20 except the crystal violet was solubilized in 95% ethanol and absorbance read at 595 nm. Viable cells in the biofilm were solubilized from a parallel microtitre plate by adding 100 lL of 0.1% Triton X-100. Preliminary tests found that Triton X-100 resulted in the solubilization of the maximal number of cells with no loss of viability. Liquid cultures from two additional, equivalent microtitre plates were removed at 24 h and wells washed with H 2 O and refilled with 100 lL of LB broth without or with various concentrations of PPMO. The plates were again incubated for an additional 24 h and then processed as described above.
Confocal microscopy
K. pneumoniae strain OR5 biofilm was grown and treated with one 24 h dose of PPMO in minimum biofilm eradication concentration (MBEC) plates, as described. 21 Cut pegs were stained with Live/Dead BacLight Bacterial Viability Kit stain (Thermo Fisher Scientific) (3 lL of SYTO 9:3 lL of propidium iodide:994 lL of 150 mM NaCl) for 15 min and rinsed with 150 mM NaCl. Pegs were then imaged on a spinning-disc confocal microscope as described. 21 Images were volumetrically rendered in Imaris software (Bitplane, Concord, MA, USA).
Ethics
All animal procedures were approved by the Oregon State University (approval number 4709) or University of Texas Southwestern Medical Center (approval number APN-2016-101626) Institutional Animal Care and Use Committees and comply with all local, state and federal laws.
Mouse survival experiments
Female BALB/c mice, aged 6-8 weeks (The Jackson Laboratory, Sacramento, CA, USA) were randomly assigned to treatment groups and then treated with 3 mg cyclophosphamide in 100 lL of PBS by intraperitoneal injection 1 and 4 days prior to infection. Mice were anaesthetized with isoflurane and infected intranasally with 3.0%10 7 cfu of K. pneumoniae NR15410 in 25 lL of PBS. Intranasal treatment with various doses of PPMO in 25 lL PBS (as indicated in figure legends) was initiated 0, 8, 24 or 48 h post infection and then repeated twice at 24 h intervals (so each mouse received a total of three doses of PPMO). Body temperature was measured in the ear using an infrared thermometer (Braun Thermoscan Pro 4000, Kaz USA, Marlborough, MA, USA).
Mouse lung burden
Six-to eight-week-old female BALB/c mice (The Jackson Laboratory, Bar Harbor, ME, USA) were treated with 3 mg cyclophosphamide in 100 lL of PBS by intraperitoneal injection 1 and 4 days prior to infection. Mice were anaesthetized with isoflurane and infected intranasally with 2.7-2.9%10 7 cfu of K. pneumoniae NR15410 (in 25 lL PBS). At 0 and 6 h post-infection, mice were treated intranasally with either 300 lg of PPMO in 25 lL PBS or 25 lL PBS. Mice were euthanized 24 h post-infection and whole lungs were collected, weighed, homogenized for 10 seconds in 1 mL of PBS and serially diluted and plated for cfu enumeration.
Statistical analysis
Data were analysed with GraphPad Prism 6 software (La Jolla, CA, USA). Treatment group cfu and mass means were compared by t-test (unpaired, two-tailed). All cfu data were transformed to log values prior to analysis. Survival was analysed by log-rank (Mantel-Cox) test.
Results
Optimization of PPMOs
Initially, 13 PPMOs were designed to target eight presumably essential genes, based on the effectiveness of PPMOs in other genera of bacteria ( Figure 1) . 21, 22 To reduce the possibility of off-target effects, PPMOs were positioned at unique 11-base sequences near the translation start codon and/or ribosome-binding site of the target gene. The 11-base length had been previously optimized to Geller et al.
inhibit bacterial and not eukaryotic gene expression. 23, 24 The design algorithm is available on-line. 25 Additionally, two control PPMOs with a scrambled sequence of bases (Scr) were also synthesized. All of the PPMOs had the same peptide [(RXR) 4 XB] attached to the 5 0 -end, except three (0802, 0017 and 1344) that used R 6 G. (RXR) 4 XB conjugates had been found previously to penetrate K. pneumoniae, 26 but R 6 G conjugates had been tested only in Pseudomonas aeruginosa Figure S2 ). The Scr PPMOs had no effect on growth.
To further optimize the PPMOs for use with K. pneumoniae, a set of AcpP PPMOs were synthesized with different peptides composed of arginine (R) and tyrosine (Y), glycine (G) or phenylalanine (F) instead of 6-aminohexanoic acid (X). The MIC of each PPMO was measured with the panel of strains. The results show that these changes made no difference in potency (Table 1) .
We assessed another feature of the PPMOs, which is attaching the peptide to either the 5 0 or 3 0 end of the PPMO. Seven PPMOs (0948, 0155, 0398, 0399, 0099, 0141 and 0205) were synthesized with the same base sequence and peptides as 0076, 0802, 0276, 0016, 0605, 0606 and 0621, respectively, except the peptides were attached to the 3 0 end. The PPMOs were tested by measuring the MIC in our panel of 40 strains. The results show that two of the 3 0 conjugates were 2-fold less potent than their 5 0 equivalents, but there was no difference in any of the other pairs (Table 1) .
Minimal bactericidal concentration (MBC)
The MBCs of 0276 and 0802 were measured in two strains from our panel of K. pneumoniae: NR15410 and NIH-1. The results show that both PPMOs were bactericidal at 2 % MIC for both strains (Figure 2) . Also, 0276 was bactericidal at 1 % MIC for both strains, whereas 0802 was only bactericidal at 1 % MIC for NR15410. Scr PPMOs had no effect on viability at any concentration tested.
Cytotoxicity
Although 11-base PPMOs do not affect the gene expression of eukaryotic cells, the sequences of both AcpP, FtsZ, RpmB and Scr PPMOs were nevertheless tested for cytotoxicity in cultures of A549 human lung epithelial cells. The results show that there was no reduction of growth or viability ( Figure S2 ).
Testing of PPMOs on biofilm
PPMOs were tested for their ability to reduce established biofilms and viable cells within biofilms. Biofilms were established in microtitre plates by growing cultures of K. pneumoniae OR5 for 24 h. Following the establishment of biofilms, the spent medium was removed and replaced with fresh broth plus 8, 16 or 32 lM AcpP-PPMO (0276 or 0802) and grown for another 24 h. Control cultures included either no PPMO or 8, 16, or 32 lM Scr PPMO (1073 or 1344). The biofilm mass and viable cells in the biofilms were then measured. The results show that 32 lM PPMO 0276 or 0802 reduced the established biofilm mass by 32% and 22%, respectively, compared with the 24 h biofilm (Figure 3a) . Furthermore, treatment with 32 lM PPMO 0276 or 0802 resulted in a 68% and 60% reduction in biofilm mass, respectively, compared with the 48 h culture without PPMO. Lower concentrations of the AcpP PPMOs resulted in a proportionally lower reduction in biofilm mass, but still significantly less biofilm than the untreated culture. The Scr PPMOs did not reduce biofilm at any concentration tested compared with the untreated culture.
Treatment of established biofilms with the AcpP PPMOs also reduced the number of viable cells in the biofilm. Treatment with 8, 16, or 32 lM AcpP PPMO 0276 resulted in significantly fewer viable cells in the biofilm compared with the untreated culture [5.6%10 7 , 3.8%10 7 or 2.0%10 7 cfu/mL, respectively, compared with 1.9%10 8 cfu/mL in the untreated culture at 48 h (Figure 3b) ]. Similar reductions in viable cells were observed with the AcpP PPMO 0802 (Figure 3b ). Neither Scr PPMO had any effect on viability of cells within the biofilm (Figure 3b) . Geller et al.
PPMO penetration of established biofilms was also measured by confocal microscopy. Biofilms were established in cultures of K. pneumoniae OR5 for 24 h without PPMO. After establishing the biofilms, the growth medium was removed and replaced with fresh medium with or without PPMO and incubated for another 24 h. The biofilms were stained with fluorescent dyes to distinguish between live and dead cells (live cells stain green, dead cells stain red). The results show that treatment with either 16 lM or 2 lM AcpP PPMO decreased viable cells by 96% (pixels " 153) and 70% (pixels " 1111), respectively, compared with the untreated biofilm (pixels " 3750). AcpP PPMO treatment also increased the ratio of dead:live cells in 16 lM (3.5:1) or 2 lM (1.3:1) biofilms as compared with untreated (1:1) and 16 lM Scr controls (0.3:1) (Figure 3c-f) . These results, taken together with those shown in Figure 3(a and b) , support the conclusion that PPMO effectively penetrated Klebsiella biofilm.
Testing of AcpP PPMO in vivo
The efficacy of the R 6 G-AcpP PPMO (0802) was evaluated in vivo using a mouse pneumonia model. Mice were infected intranasally with the MDR clinical isolate K. pneumoniae NR15410 and then treated intranasally once daily for 3 days with various amounts of PPMO from 12.5 lg to 600 lg (0.6 to 30 mg/kg). Control groups were infected and treated similarly with either PBS or an Scr PPMO. The results show dose-dependent responses. Survival was 89%, 62% and 33% for mice treated with 600 lg, 200 lg or 67 lg (30, 10 and 3.3 mg/kg) of R 6 G-AcpP PPMO, respectively (Figure 4a ). This was significantly greater (P , 0.002) than mice treated with either PBS or the Scr PPMO. All mice treated with lower amounts of the AcpP PPMO, PBS or 600 lg (30 mg/kg) of Scr PPMO died by day 5 post-infection. Mice treated with a lower dose (200 lg, 10 mg/kg) of Scr PPMO also died by day 5 (data not shown), strongly suggesting that deaths were not caused by toxicity of the Scr PPMO. Body temperature of surviving mice began to recover between 3 and 5 days post-infection, whereas it continued to decrease after day 2 or 3 in all mice that ultimately did not survive (Figure 4b) .
The R 6 G-AcpP PPMO (0802) was also tested therapeutically by administering it post-infection. Groups of mice were infected as described above and then treated with the first dose of 600 lg (30 mg/kg) of PPMO at 0 h, 8 h, 24 h or 48 h post-infection. Each group was treated twice more at 24 h intervals. When treatment was not delayed, 71% of the mice survived (Figure 5a) . Delaying treatment for 8 h resulted in 33% survival, which is significantly greater than the PBS control group. There were no survivors in the PBS-treated group or when initial treatment was delayed for 24 or 48 h. However, median survival time in the 8 h (5.0 days) and 24 h (4.0 days) delayed-treatment groups was significantly (P , 0.01) greater than that in the PBS-treated group (3.0 days). Body temperature decreased less in mice treated initially at 0 or 8 h compared with groups treated initially at 24 or 48 h, or with PBS ( Figure 5b) .
In other experiments, the bacterial burden in the lungs of infected mice was measured. Groups of mice were infected intranasally and then treated intranasally at 0 and 6 h post infection with 300 lg (15 mg/kg) of R 6 G-AcpP PPMO (0802), R 6 G-Scr PPMO (1344) or PBS. After 24 h post-infection, lungs were removed, homogenized and spread on Petri dishes to determine viable bacteria. The results showed a highly significant (P , 0.0001), 3-log reduction in viable bacteria from the lungs of mice treated with AcpP PPMO 0802 compared with the mice treated with PBS ( Figure 6 ). No statistically significant (P . 0.05) reduction was found in the group treated with Scr PPMO (1344) compared with the group treated with PBS.
Discussion
Our results show that PPMOs targeted to essential genes in K. pneumoniae inhibited growth in pure cultures of a panel of 40 diverse strains. The MIC 75 values ranged from 0.5 lM to .16 lM. The MBC of two PPMOs targeted to acpP were either 1 or 2 % MIC, depending on the strain used for testing. These results are similar to previous reports that showed in vitro growth inhibition of Geller et al.
K. pneumoniae using peptide-conjugated peptide nucleic acids targeted to various essential genes. 27, 28 It appears that the AcpP PPMOs are at least 20 times more potent than the peptideconjugated peptide nucleic acids targeted to gyrA, ompA 28 or rpoD. 27 These differences in potency may be attributed to differences in the target gene, the membrane-penetrating peptides, the strains or methods used to measure MIC, or the position of the oligomers relative to the start codons or ribosome-binding sites. acpP appears to be a superior target across numerous pathogens. One possible explanation for this finding is that small decreases in acpP expression have a greater impact on growth rate than similar decreases in expression of other known essential genes. 29 Importantly, PPMOs retained their activity in MDR strains of Klebsiella, which is similar to our experiences with other Gramnegative pathogens.
An unexpected result was the ability of the PPMOs to reduce both biofilm mass and viability of K. pneumoniae within established biofilms. Biofilms protect embedded bacteria by reducing the effectiveness of antibiotics, bacteriophage and the immune system. 30 Although the exact mechanism(s) of biofilm protection against antibiotics is controversial, it seems dependent on the bacterium and the structures of the biofilm and antibiotic and not necessarily related to diffusion limitations linked to molecular weight. [30] [31] [32] Our results are consistent with the hypothesis that Klebsiella biofilm does not pose a diffusion limitation, since the molecular weight of PPMOs is about 10-20 times that of most common antibiotics. Although the mechanism by which PPMOs reduce biofilm mass and gain access to kill the bacteria is unknown, our results from treating the established biofilm with PPMO in PBS are consistent with the PPMO penetrating the biofilm to gain access to the pathogen. Our results are inconsistent with the PPMO acting only on the planktonic cells. In addition, our results are inconsistent with the membrane-penetrating peptide portion of the PPMO simply solubilizing the biofilm, since an Scr PPMO with the same peptide attached did not reduce biofilm mass. These data suggest that PPMOs penetrate Klebsiella biofilms, kill cells within the biofilm and reduce biofilm mass. We have demonstrated a similar ability of PPMOs in biofilms of Pseudomonas.
21
The Scr PPMO 1344 showed a slight, but statistically insignificant, reduction of bacterial lung burden. However, this was not sufficient to increase survival. No effect of the Scr PPMO was found in any of the in vitro assays. A previous report also found a positive effect of an Scr PPMO in vivo, but not in vitro. 16 This trend seems to point to a non-sequence-specific effect. The cause of this effect is unknown, but we speculate that it might result from an interaction of the PPMO with the innate immune system. Alternatively, it is conceivable that it is related to changes in vasculature, possibly mediated through nitric oxide.
While previous reports have demonstrated the effectiveness of antisense antimicrobial oligomers in pure culture and in tissue culture, 27 ,28,33 we believe that this is the first vetted report of the Morpholino oligomers tested against Klebsiella in vivo JAC effectiveness of an antisense oligomer against K. pneumoniae in an animal model. Here we have shown that an AcpP PPMO improved survival and reduced morbidity in a dose-dependent manner and in a dosage range that is clinically achievable (3-30 mg/kg/dose once per day). The PPMO was well-tolerated in vivo and was effective therapeutically. Because the amount of each dose that actually reaches the site of infection in the lung may vary slightly with each intranasal administration, it is possible that the results underestimate the potency and efficacy of the AcpP PPMO. These results open up a new possibility for future studies that will validate acyl carrier protein as the target, establish the pharmacokinetics and pharmacodynamics, and test the tolerability and toxicity in vivo. PPMOs have the potential for clinical applications against MDR Klebsiella. Geller et al.
